Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are comparing two treatments for people with non-muscle invasive bladder cancer. If you take part in this study, you will be randomly assigned to get either:
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Sacituzumab govitecan targets and destroys cells that make a protein called TROP-2. Researchers have found this protein to be expressed on mesothelioma cells. By destroying these cells, sacituzumab govitecan may help slow or stop the growth of your cancer. It is given intravenously (by vein).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are comparing three different treatments for multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment. If you join this study, you will be randomly assigned to get one of these treatments:
The purpose of this study is to assess the safety and effectiveness of treating rare advanced genitourinary cancers with the immunotherapies nivolumab and ipilimumab plus the drug cabozantinib.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
